Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
Nuvectis Pharma Inc NVCT
$21.52
▼ -5.45%
($-1.24)
📅 Earnings This Week
Open
$23.12
Prev Close
$22.76
Day Range
$21.21 – $23.12
52W Range
$5.55 – $29.28
Market Cap
$678.43M
Beta
-0.25
EPS (TTM)
$-1.20
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2022-02-04 |
| Shares Out. | 31,530,000 |
| Website | nuvectis.com/ ↗ |
| Phone | 13608377232 |
| Employees | 13 |
| Net Income | -$6.1M |
| Total Assets | $25.4M |
| Total Liabilities | $11.2M |
| Equity | $14.2M |
About Nuvectis Pharma Inc
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Nuvectis Pharma Inc is a publicly traded company under the ticker symbol NVCT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-07-01)
📰 Latest News for NVCT
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Nuvectis Pharma's Ciprocopan Receives Marketing Approval From National Medicinal Products Administration Of China To Treat Paroxysmal Nocturnal Hemoglobinuria
Ryanair Posts Weak Q1 Results, Joins HDFC Bank And Other Big Stocks Moving Lower In Monday’s Pre-Market Session